You are here: Industry Insights > PROTAC

News List

Favored by Capital and Hot Among Pharma Companies, This Small-molecule Degradation Agent Company Has Great Potential PharmaSources/Xiaobing
March 21, 2022
While many pharmaceutical companies are chasing targeted and immunotherapy therapeutic drugs, protein degradation therapy has also attracted the attention of more and more companies and has become another new direction in the field of new drug R&D.
With the BGB-16673 Clinical Trials of BeiGene Launched, PROTAC Leads a Brand New Trend of Global Competition PharmaSources/Wanghong
March 21, 2022
On February 28, BGB-16673, a BTK-targeted PROTAC drug of BeiGene, was launched for clinical trials for the first time in China.
Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China prnasia
July 28, 2021
Kintor Pharmaceutical Limited announced today that the company has dosed the first batch of subjects in its phase I clinical trial of GT20029 in China.
Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne prnasia
July 14, 2021
Kintor Pharmaceutical Limited today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug GT20029 for treating androgenetic alopecia (AGA) and acne subjects.
Kintor's GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA prnasia
February 02, 2021
Kintor Pharmaceutical Limited is pleased to announce that the investigational new drug application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration of China.
Leukemia, lymphoma squarely in sights of new class of drugs worldpharmanews
December 09, 2019
UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of ...
Eisai forms PROTACs research collaboration pharmaceutical-technology
July 09, 2019
Eisai has formed a research collaboration to support oncology drug discovery using proteolysis targeting chimeras (PROTAC), which comprise two covalently linked protein-binding molecules.